Compare Stocks: BVNRY, SMMT, BMRN, and KYMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$57.23 +0.9%	$59.04	$49.26 ▼ $70.98	$11.09B	0.21	2.12 million shs	369,637 shs
BVNRY Bavarian Nordic	$11.68 -0.9%	$11.48	$8.67 ▼ $12.72	$2.78B	1.33	3,300 shs	301 shs
KYMR Kymera Therapeutics	$128.34 +0.9%	$116.94	$62.13 ▼ $142.92	$10.96B	2.04	768,177 shs	365,246 shs
SMMT Summit Therapeutics	$14.36 -4.7%	$16.47	$12.07 ▼ $29.23	$11.48B	-1.49	4.64 million shs	3.39 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-2.79%	+0.99%	+4.27%	-15.83%	+2.49%
BVNRY Bavarian Nordic	+0.15%	-2.98%	+0.26%	+23.74%	+21.85%
KYMR Kymera Therapeutics	-5.69%	-0.74%	+19.21%	+8.33%	+100.17%
SMMT Summit Therapeutics	-9.44%	+6.20%	-2.90%	+12.88%	-19.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRN BioMarin Pharmaceutical	$57.23 +0.9%	$59.04	$49.26 ▼ $70.98	$11.09B	0.21	2.12 million shs	369,637 shs
BVNRY Bavarian Nordic	$11.68 -0.9%	$11.48	$8.67 ▼ $12.72	$2.78B	1.33	3,300 shs	301 shs
KYMR Kymera Therapeutics	$128.34 +0.9%	$116.94	$62.13 ▼ $142.92	$10.96B	2.04	768,177 shs	365,246 shs
SMMT Summit Therapeutics	$14.36 -4.7%	$16.47	$12.07 ▼ $29.23	$11.48B	-1.49	4.64 million shs	3.39 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRN BioMarin Pharmaceutical	-2.79%	+0.99%	+4.27%	-15.83%	+2.49%
BVNRY Bavarian Nordic	+0.15%	-2.98%	+0.26%	+23.74%	+21.85%
KYMR Kymera Therapeutics	-5.69%	-0.74%	+19.21%	+8.33%	+100.17%
SMMT Summit Therapeutics	-9.44%	+6.20%	-2.90%	+12.88%	-19.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRN BioMarin Pharmaceutical	2.80	Moderate Buy	$87.22	52.41% Upside
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
KYMR Kymera Therapeutics	2.89	Moderate Buy	$139.16	8.43% Upside
SMMT Summit Therapeutics	2.58	Moderate Buy	$28.61	99.23% Upside

Current Analyst Ratings Breakdown

Latest BVNRY, SMMT, BMRN, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/13/2026	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$119.00 ➝ $103.00
11/4/2026	BMRN BioMarin Pharmaceutical	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$87.00 ➝ $86.00
11/3/2026	BMRN BioMarin Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
11/3/2026	BMRN BioMarin Pharmaceutical	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$97.00 ➝ $94.00
11/3/2026	BMRN BioMarin Pharmaceutical	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Hold	$70.00 ➝ $66.00
11/3/2026	BMRN BioMarin Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$122.00 ➝ $119.00
11/3/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$60.00
11/3/2026	BMRN BioMarin Pharmaceutical	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Perform	$62.00 ➝ $60.00
11/2/2026	KYMR Kymera Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$139.00 ➝ $170.00
10/30/2026	KYMR Kymera Therapeutics	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$136.00 ➝ $150.00
10/30/2026	KYMR Kymera Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$112.00 ➝ $116.00

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRN BioMarin Pharmaceutical	$3.22B	3.44	$2.80 per share	20.44	$32.30 per share	1.77
BVNRY Bavarian Nordic	$945.43M	2.94	$1.33 per share	8.76	$8.20 per share	1.42
KYMR Kymera Therapeutics	$39.21M	279.43	N/A	N/A	$18.91 per share	6.79
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRN BioMarin Pharmaceutical	$348.90M	-$0.10	N/A	11.13	0.78	-0.52%	5.58%	3.51%	N/A
BVNRY Bavarian Nordic	$208.23M	$0.99	11.80	N/A	N/A	24.36%	11.97%	10.55%	N/A
KYMR Kymera Therapeutics	-$311.35M	-$3.62	N/A	N/A	N/A	-285.33%	-22.39%	-20.48%	N/A
SMMT Summit Therapeutics	-$1.08B	-$1.07	N/A	N/A	N/A	N/A	-138.82%	-117.11%	N/A

Latest BVNRY, SMMT, BMRN, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	BVNRY Bavarian Nordic	N/A	$0.28	N/A	$0.28	N/A	N/A
11/2/2026	Q3 2026	BMRN BioMarin Pharmaceutical	-$0.0493	$0.23	+$0.2793	-$0.63	$1.02 billion	$1.02 billion
10/29/2026	Q3 2026	KYMR Kymera Therapeutics	-$1.26	-$1.32	-$0.06	-$1.32	$3.28 million	$1.35 million
8/21/2026	Q2 2026	BVNRY Bavarian Nordic	N/A	$0.46	N/A	$0.46	N/A	$316.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRN BioMarin Pharmaceutical	0.56	2.44	1.32
BVNRY Bavarian Nordic	N/A	6.53	3.91
KYMR Kymera Therapeutics	N/A	11.13	11.13
SMMT Summit Therapeutics	N/A	5.99	5.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRN BioMarin Pharmaceutical	98.71%
BVNRY Bavarian Nordic	N/A
KYMR Kymera Therapeutics	N/A
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
BMRN BioMarin Pharmaceutical	0.68%
BVNRY Bavarian Nordic	N/A
KYMR Kymera Therapeutics	15.98%
SMMT Summit Therapeutics	81.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.70 million	192.38 million	Optionable
BVNRY Bavarian Nordic	1,692	237.80 million	N/A	Not Optionable
KYMR Kymera Therapeutics	285	85.37 million	71.73 million	Optionable
SMMT Summit Therapeutics	265	799.76 million	145.56 million	Optionable

BVNRY, SMMT, BMRN, and KYMR Headlines

Recent News About These Companies

Summit Therapeutics PLC (SMMT) - What Are Researchers Saying About This Stock?

November 11 at 4:13 AM | marketbeat.com

Wall Street Analysts See a 62.33% Upside in Summit Therapeutics (SMMT): Can the Stock Really Move This High?

November 10 at 10:56 AM | zacks.com

Summit Therapeutics (SMMT) Stock Looks Richly Priced On Its 7x Run

November 10 at 7:34 AM | finance.yahoo.com

102,550 Summit Therapeutics PLC $SMMT Shares Purchased by Hohimer Wealth Management LLC

November 9, 2026 | marketbeat.com

1,130,537 Summit Therapeutics PLC $SMMT Shares Bought by Candriam S.C.A.

November 9, 2026 | marketbeat.com

FY2026 Earnings Estimate for SMMT Issued By HC Wainwright

November 9, 2026 | americanbankingnews.com

What is HC Wainwright's Estimate for SMMT FY2026 Earnings?

November 9, 2026 | marketbeat.com

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘

November 8, 2026 | stocktwits.comS

Analysts Are Bullish on These Healthcare Stocks: Summit Therapeutics (SMMT), Lexicon Pharmaceuticals (LXRX)

November 7, 2026 | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Breaks Above 200 Day Moving Average - Time to Sell?

November 7, 2026 | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Break Above 200-Day Moving Average - Should You Sell?

November 7, 2026 | marketbeat.com

SMMT's Q3 Earnings Beat Estimates, Ivonescimab Development in Focus

November 5, 2026 | zacks.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO) and Summit Therapeutics (SMMT)

November 4, 2026 | theglobeandmail.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

November 4, 2026 | businesswire.com

Summit Therapeutics (SMMT) Set to Post Earnings on Monday

November 4, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Climb 10.5% - Should You Buy?

November 3, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7.5% - What's Next?

November 2, 2026 | marketbeat.com

Summit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI Deal

October 30, 2026 | finance.yahoo.com

Summit Therapeutics (NASDAQ:SMMT) Shares Break Above 200 Day Moving Average - Here's What Happened

October 30, 2026 | marketbeat.com

Simplify Asset Management Inc. Buys New Position in Summit Therapeutics PLC $SMMT

October 29, 2026 | marketbeat.com

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts (SMMT)

...

October 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVNRY, SMMT, BMRN, and KYMR Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

$57.22 +0.53 (+0.93%)

As of 02:13 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Bavarian Nordic OTCMKTS:BVNRY

$11.68 -0.11 (-0.93%)

As of 09:45 AM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Kymera Therapeutics NASDAQ:KYMR

$128.34 +1.17 (+0.92%)

As of 02:13 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$14.36 -0.71 (-4.72%)

As of 02:13 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BVNRY, SMMT, BMRN, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BVNRY, SMMT, BMRN, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BVNRY, SMMT, BMRN, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVNRY, SMMT, BMRN, and KYMR Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Bavarian Nordic OTCMKTS:BVNRY

Kymera Therapeutics NASDAQ:KYMR

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BVNRY, SMMT, BMRN, and KYMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BVNRY, SMMT, BMRN, and KYMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BVNRY, SMMT, BMRN, and KYMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BVNRY, SMMT, BMRN, and KYMR Company Descriptions

BioMarin Pharmaceutical NASDAQ:BMRN

Bavarian Nordic OTCMKTS:BVNRY

Kymera Therapeutics NASDAQ:KYMR

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools